Experimental IPF Therapy BBT-877 Gets FDA’s Orphan Drug Status

Experimental IPF Therapy BBT-877 Gets FDA’s Orphan Drug Status

Bridge Biotherapeutics’ investigational therapy candidate BBT-877 for idiopathic pulmonary fibrosis (IPF) has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA). According to the company, BBT-877 is a best-in-class autotaxin (ATX) inhibitor, and a potential anti-inflammatory and anti-fibrotic treatment for IPF. Studies have shown…

PDGFR-β Inhibition Prevents Lung Fibrosis in Mouse Model of PF

Blocking the platelet-derived growth factor receptor-beta (PDGFR-β) prevents lung fibrosis in a mice model of pulmonary fibrosis, a study says. Based on these observations, scientists believe that PDGFR-β blockade may someday be a viable therapeutic option for patients with idiopathic pulmonary fibrosis (IPF). The findings of the study, “Blockade…

Dealing with a Recent Exacerbation

Pulmonary fibrosis (PF) patients often experience a sudden worsening of their disease — this is referred to as an “acute exacerbation.” An event such as infection often triggers the exacerbation, and sometimes the cause is unknown. About three weeks ago, I started needing more oxygen. I now require 1…

Introducing Your Chronic Illness in a New Relationship

Relationships make the world go round, and connection with others is an essential part of our human existence. These range from the intimate ties between spouses to the close bonds between parents and children, siblings, and grandparents. Friendships and relationships with co-workers are also important in our…

Sprycel/Quercetin Combo Therapy Improves Physical Function in IPF Patients, Phase 1 Trial Shows

A Phase 1 trial shows that combining Sprycel (dasatinib) with the plant-based flavonoid quercetin improved the physical function of people with idiopathic pulmonary fibrosis (IPF). However, patients’ pulmonary function remained unchanged. The study, “Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study” was published…